The purpose of this research work was to develop and evaluate matrix-type transdermal therapeutic system containing Irbesartan with different ratios of hydrophilic and hydrophobic polymeric combinations. Formulations were prepared by using solvent evaporation technique. Matrix type transdermal film of Irbesartan, antihypertensive drug were prepared using different polymers like Ethyl Cellulose, Hydroxy Propyl Methyl Cellulose and Eudragit RL100 in varied ratios. The present study aims to formulate and evaluate Transdermal film for sustained release of Irbesartan. The results suggested no physicochemical incompatibility between the drug and the polymers. All formulations carried dimethyl sulfoxide as penetration enhancer and propylene glycol as plasticizer in chloroform and ethanol as solvent system. The diffusion studies were performed by using modified Franz diffusion cells. The formulation, F1 with combination of polymers (4:1) emerging to be ideal formulations for Irbesartan. The developed transdermal films increase the efficacy of for the therapy of hypertension, chronic stable angina pectoris, and Prinzmetal's variant angina. Physicochemical parameters were characterized. The permeability study indicates that the drug is suitable for Transdermal drug delivery. The film were evaluated for various parameters like Thickness, Water-Vapour permeability, Tensile Strength, moisture loss, moisture uptake, film folding endurance, Drug Content, flatness, surface pH, swellability, % elongation, skin irritation and Diffusion studies. The films were further evaluated by DSC to ensure uniform distribution of the drug and compatibility of drug with polymer. The Optimized formulation containing HPMC: Eudragit RL100 (4:1), with enhancer DMSO showed 87.13% drug release after 24 hours.
